Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab combination study in adults with relapsed/refractory multiple myeloma
NL-OMON59992Phase 1Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of linvoseltamab in multiple myeloma (MM), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Primary endpoint(s). Planned start Aug 2022; status: not yet recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59992.